Four basic models for characterizing indirect pharmacodynamic responses after drug administra-
INTRODUCTION
The growing body of pharmacokinetic/pharmacodynamic literature emphasizes the important niche created by pharmacodynamic modeling. Only a small percentage of studies have jointly measured drug levels and pharmacologic effects. When the pharmacological effects are seen immediately and are directly related to the drug concentration, a pharmacodynamic model such as a linear model, an Emax model, or a sigmoid Emax model is applied to characterize the relationship between drug concentrations and effect. When the pharmacologic response takes time for development, and the observed response is not apparently related to plasma concentrations of the drug, a "link model" is usually applied to relate the pharmacokinetics of the drug with its pharmacodynamics (1) . The most commonly encountered application presently involves using the effect-compartment approach which assumes that the rate of drug distribution to and from the hypothetical effect site will determine the rate of onset of effect. Following the modeling of d-tubocurarine by Sheiner et al. (2) , several other methods have been investigated including the semiparametric approach (3) . This topic has been the subject of comprehensive reviews (4, 5) .
Many drug responses, however, may be considered indirect in nature. Earliest characterizations of an indirect response examined the anticoagulant effect of warfarin (6, 7) . Other response models such as direct suppression models for glucocorticoid responses have been developed (8) . A two-compartment closed model has been described for the trafficking of basophils following methylprednisolone exposure (9) . The trafficking of helper T lymphocytes (10) and natural killer cells (11) due to glucocorticoid exposure have also been modeled. Other processes such as prolactin suppression (12) and osteocalcin suppression (13) have also been studied. More complex models of indirect pharmacologic action such as the receptor/gene-mediated induction of the enzyme tyrosine aminotransferase (TAT) require a multistep cascade of events (14) .
In each of the above situations, following the dose of the drug, there is a slow accretion of the drug response which is governed by the inhibition or stimulation of factors controlling this response. In actuality, these can produce either an increase or decrease in the observed response variable depending on whether the input or disposition process is inhibited or stimulated. In the present report we propose a family of four basic indirect response models to account for the most commonly observed types of responses. Our main purpose is to present the theoretical basis and observed response patterns for these basic indirect response models. A second objective is to show the limitations of applying the sigmoid Emax model using the effect-compartment approach (distributive sigmoid Emax model) to fit data that are described by indirect models.
THEORETICAL
The basic premise of this study is that a measured response (R) to a drug may be produced by indirect mechanisms; for example, factors controlling the input or production (kin) of the response variable may be either inhibited or stimulated, or the determinants of loss (kout) of the response variable may be inhibited or stimulated. The rate of change of the response over time with no drug present can be described by dR -~i,-kou," R
dt where ki, represents the zero-order constant for production of the response and kout defines the first-order rate constant for loss of the response. It is assumed that kin and kout fully account for production and loss of the response. The response variable R may be a directly measured entity or an observed response which is immediately proportional to the concentration of R. In 
Cp + IC5o
where Cp represents the plasma concentration of the drug as a function of time and IC5o is the drug concentration which produces 50% of maximum inhibition achieved at the effect site. Accordingly, the rate of change of drug response in Model 1 can be described by 
dt Note thatin Models 1 and 2, an Emax for maximum inhibition is implied by the assumption that inhibition can completely negate the functioning of the affected factors, i.e., when Cp>>ICso, I(t) approaches zero. In addition, note that I(t) approaches unity when Cp<<ICso.
In Cp<<ECso, the net effect approaches the baseline effect, i.e., S(t)~ 1.
Model 3 represents drug response that accrues from stimulation of the factors that control the production of the response variable according to dR --ki. "S(t) -kout" R (6) dt When drug response is attibuted to factors controlling the dissipation of the response variable, Model 4 describes the rate of drug response by
As stationarity is assumed for all models, the response variable (R) begins at a predetermined baseline value (Ro), changes with time following drug administration, and eventually returns to Ro. Thus kin = kout" Ro (8) which reduces the number of operative parameters in these models. Equations (2) and (5) entail an assumption that drug effects correlate directly to plasma drug concentrations; thus, Cp can be generated using classical pharmacokinetic models describing drug input and disposition rates.
In these models, R represents the measured response variable while the effect site represents a separate locus of drug action where the mechanism of action controls either stimulation or inhibition of the designated controlling process (ki, or ko,t).
METHODS

Pharmacokinetics
Methylprednisolone (MP) was chosen as a model drug for simulation since its pharmacokinetics can be described using a linear, one-compartment model, and its pharmacodynamic effects are indirect. Pharmacokinetic profiles were generated for single intravenous (iv) doses (D) administered as a bolus or as a constant infusion. In order to produce a wide range of responses, four dose levels were selected: 1, 10, 100, and 1000 mg. Literature values for a one-compartment volume of distribution (V) equal to 86 L and an elimination rate constant (k~0 equal to 0.29 hr -j were selected to simulate plasma MP concentration-time profile using {D. lOOO~ (9) where the factor 1000 converts the plasma concentrations to ng/ml. Plasma drug concentrations following administration of single iv infusions over 6 hr were simulated using
Cp=l------V-~ ) e -k~
where T= t when t < T, T= T when t > T, and T is the infusion time (6 hr).
Distribution Sigmoid Emax Model
The indirect response models produce a delayed response that can be misinterpreted as caused by the rate of drug distribution to an effect compartment. Data obtained from the simulations were refitted based on such a model to evaluate the two approaches.
The sigmoid Em~x equation that was applied to data that behaved as an inhibitory response is
E,,,~,,.C" E E=Eo (11)
IC~o + C~
where Eo represents the baseline effect prior to drug administration, n is the sigmoidicity factor, and CE is the drug concentration at the effect site. The data were also fitted with a simple distributive Em~x model, i.e., with n = 1 in Eq. (11) . All other parameters remain analogous to those previously defined.
The sigmoid Emax equation that was applied to data that behaved as stimulatory responses is
ECho + C~ Apparent effect site concentration (CE) VS. time profiles were generated for the one-compartment, iv bolus administration according to D. 1000"keo (e_k,r,_e_k~
where k~o represents the first-order rate constant for drug loss from the effect site. Equations (1 l) [or (12) ] and (13) were fitted simultaneously to obtain 
where T is defined as in Eq. (10) The differential equations for Models 1-4 were used in the PCNONLIN program (SCI Software Inc., Lexington KY) to simulate the response versus time profiles. Initial parameter values and initial conditions (Table I) were obtained from literature values for Model 1 as applied to basophil cell trafficking (9) . The initial conditions (Ro) for Models 2 and 3 and the E,,a, values for Models 3 and 4 were chosen arbitrarily.
The distributive sigmoid Em,x models were fitted to selected data points from simulated pharmacodynamic profiles using PCNONLIN. A weight of 1/y was used except for Model 1 for the 1000-mg dose and for simultaneous fitting of all doses in Model 2, where the data fitted best when no weighting schemes were used.
RESULTS
Model Fitting
The results of simulating the pharmacokinetic profiles of methylprednisolone for four dose levels are shown in Fig. 2 . Linear kinetics and a wide range of plasma concentrations are evident. (3) to plasma drug concentrations generated by Eq. (9). The top panel shows how the inhibitory indirect response mechanism produces a slow diminution of the response variable with a maximum inhibitory response observed serveral hours after drug administration. Thereafter, the response gradually returns to the baseline with a later return found with the larger does. The time of occurence of maximum inhibition (Tmax) shifts to later times with larger doses and these values (estimated from simulations) are listed in Table  II . The net response is proportional to the log of dose. The middle panel shows a hysteresis plot of response versus plasma drug concentration. During the time when drug concentration and responses are returning to baseline, there is a near superpositioning of the curves. The lower panel shows the fitting of the data to the distributive sigmoid Em,x model individually for the four doses of the drug. figure) . Figure 4 shows iv infusion data for Model 1 generated by applying Eq. (14) to MP plasma infusion data simulated by Eq. (10). The general observations are similar to those found in Fig. 3 . The middle panel of Fig.  4 , however, shows the more common expression of hysteresis generally associated with an effect compartment. Note that the direction of the curves is clockwise as a decreasing response is plotted on the ordinate. Again, the lower panel shows poor fitting of the data (using a distributive sigmoid Emax model) at higher doses. Table III shows the dose dependency of the parameter estimates obtained from individual fitting of the doses with this model.
Besides the marked changes in keo, IC5o, and n with dose, these apparent parameters differ from values generated for Model 1 data from the preceding iv bolus base.
In Fig. 5 , the three panels characterize Model 2 which exemplifies inhibition at the site of loss of drug response. The initial responses for all doses superimpose. The time of occurrence of the maximum response is dependent on the dose (see Table II to the other three models, the responses return to baseline more quickly. The hysteresis plot in the middle panel of Fig. 5 demonstrates counterclockwise curves as an increasing response is plotted on the ordinate. In the lower panel, which shows the fitting of the data with a distributive sigmoid Emax model, the larger doses reveal a poor fitting as seen previously in Figs. 3  and 4 . The estimated parameters, listed in Table III , vary with dose with the koo values affected most.
The pharmacodynamic profiles resulting from simulations when Model 3 (stimulation of the factors controlling the production of the drug response) is applied are shown in Fig. 6 . Compared to Model 2, the time of maximum response does not shift as such with dose (Table II) . As in Model 2, the middle panel shows an anticlockwise direction of the hysteresis. The lower panel shows that, for this model, all the dose levels were fitted well with the distributive sigmoid model when the fittings were performed individually for each dose. However, as seen in Table III , the parameters showed similar dose dependency as seen with the other models. An attempt to fit all four doses simultaneously resulted in poor fitting of all profiles (not shown in figure) . Figure 7 shows the pharmacodynamic profiles resulting from Model 4 (stimulation of the factors controlling the toss of response). The time for maximal response shifted only slightly with dose (Table II) . As seen in Figs. 3 and 4, the hysteresis in the middle panel is clockwise since a decreasing response is plotted. The lower panel shows that the distributive sigmoid Era,• model fitted the data from the lower doses better than the data from the higher doses. Table III shows similar dose dependency of the estimated parameters seen with the other models, with the ICso changing severely (150-fold range). As expected, a simultaneous fit of all four dose levels resulted in a poor fitting.
DISCUSSION
Indirect Response Patterns
The four basic indirect response models were developed to account for the most commonly expected types of responses. These models have common characteristics as observed from the plots of the simulated data. The net response increases with dose until a maximum value is obtained. Models 1 and 4 express this maximum response as a theoretical minimum of zero, although Model 4 may not reach zero depending on the value set for Em,x. In all four models, the time of occurence of the maximum or minimum response is shifted to later times as the dose increases. The initial rate of change of the response maintains the same value, governed by kout, independent of dose. This phenomenon was observed previously with the pharmacokinetic/pharmacodynamic modeling of glucocorticoid suppression of basophil trafficking (8, 9) . In addition, all four models show a slow return to baseline which proceeds to occur when plasma drug concentrations decline to very low values (below IC5o or ECso). The equations predict and the curves demonstrate that the return rate of responses with the larger doses are essentially parallel as they are governed by the zero-order constant, kin. When the responses are nearly back to baseline, the curves are a function of kin, kout, and the changing value of R, which render these as nonlinear functions.
As the models assumed stationarity, all curves return to the original baseline. As the four basic indirect response models yield both common and differential characteristics, these models may serve to classify appropriately collected dose-response data.
Typically, experimental data demonstrate either an increased or a diminished response with time after dosing of the drug. Pharmacologic insight into the mechanism of action of the drug is needed to identify whether inhibition or stimulation is occurring. In the case of methylprednisolone effects on basophils and helper T cell trafficking, Model 1 produced ICs0 values that were similar to receptor KD values supporting an assumption of inhibition of kin (8-10).
Effect Compartment Model
The basic appearance of an effect compartment model with distribution governing drug movement to and from the effect site may seem analogous to the indirect response model kin and kout processes. Part of the purpose of this work was to assess what happens when the effect compartment model is used in characterizing data which are more accurately described by an indirect mechanism of action. The model used for the present fittings (distributive sigmoid Emax model) was found to fit the data better than the simple Ema~ model using an effect compartment (data not presented).
Generally the distributive sigmoid Em,x model could fit individual response patterns extremely well with the poorest fitting observed with larger drug doses. However, when common parameters were sought in jointly fitting of all dose levels with this model, overall fitting was poor as the distributive model requires that all dose levels produce maximum effect at the same time. The indirect models entail a later Tmax with larger drug doses. As expected, most parameters obtained from simultaneous fitting (Table III) fall between the range of the individual estimates. However, there are some inconsistencies, particularly in the n and Em,x values which may be a limitation of the fitting algorithm. However, using a different algorithm (NelderMead vs. Gauss-Newton modifications in PCNONLIN) did not change this situation.
The dose dependency of the estimated parameters (shown in Table III) creates a biologically implausible situation where the sensitivity (IC5o/EC5o), the capacity (Emax), and the n value for a system change with dose. Thus, the distributive model, while seemingly capable of characterizing the data, has severe limitations when applied to fitting data described by an indirect response.
There have been situations in pharmacodynamic modeling of prednisolone (15) , methylprednisolone (16) , and dexamethasone (17) where these limitations have been observed.
General Applications
Since many drugs act by inhibiting or stimulating the release of an endogenous physiological factor, the models presented in this paper may have a broad general applicability. Besides the examples cited, other classes of drugs for which these or more complex models maybe applicable include histamine H2-receptor antagonists, such as cimetidine, which reduce gastric acid secretion (18) ; oral hypoglycemic agents, such as tolbutamide, which lower blood glucose levels by stimulating the secretion of insulin (19) ; angiotensin-converting enzyme inhibitors, such as captopril, which reduce blood pressure by inhibiting the formation of angiotensin II (20) ; aldose reductase inhibitors, such as AL 1576, which inhibit the formation of sorbitol from glucose (21) ; and dopamine antagonists, such as remoxipride, which stimulate the secretion ofprolactin (22) . It is apparent that the pharmacodynamics of these drugs may be characterized using Model 1 or 3. The effects of reversible anticholinesterase agents (e.g., physostigmine) which inhibit the enzymatic breakdown of acetylcholine may be characterized using Model 2. Examples of Model 4 type drugs include diuretics such as furosemide which stimulate the secretion of electrolytes and urine (:23). Other classes of drugs whose actions might be characterized by these models include cholinergic agonists/antagonists, adrenergic agonists/antagonists, opioid analgesics and antagonists, nonsteroidal antiinflammatory agents, 5-hydroxytryptamine antagonists, hormones, and hormone antagonists.
The four basic indirect response models proposed in this paper represent the most simplistic approaches to modeling drug effects on the input and output processes. It is logical to expect that more complex models involving partial inhibition or stimulation or joint effects on input and output processes may be adapted. As found for cortisol and helper T cell suppression, kin may be a circadian rather than zero-order constant (8, 10) . It may be necessary to add the sigmoidicity factor (n) to the I(t) or S(t) functions for some drug effects. The locus of drug action may correspond to a tissue site which may require a more complex model involving a distribution function. If more than one active substance is present (such as an active metabolite) at the site(s) of action, it may be necessary to adjust the models to accommodate for the action of each. Finally, ki, and kout may control biological mediators which, in turn, require time to evoke the observed response. Thus a cascadetype model may be required (14) .
This report proposes four basic models to represent drug responses that are characterized by indirect mechanisms. The actual response patterns of specific drugs may vary with the selection of constants and initial parameter estimates other than those used to simulate the data presented in this pape r . Initial estimates of parameters for Models 1-4 may be obtained from experimental data following an iv bolus dose of drug as described in this section. 
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